Women make up nearly two-thirds of people living with Alzheimer's disease, and a new review in The Journal of Clinical Investigation argues that longer life expectancy does not fully explain the gap. Dr. Lisa Mosconi, a neuroscientist who specializes in women's brain health, examined how midlife hormonal shifts and neuroendocrine aging shape Alzheimer's risk, and concluded that the menopause transition may itself be a critical window for prevention.
The biological case rests on what happens to the brain during that transition. According to the review, hormonal changes in midlife can alter brain biology and metabolism in ways that may contribute to the buildup of amyloid plaques and tau tangles, the two hallmark markers of Alzheimer's pathology. That reframes menopause from a reproductive milestone into a period of measurable neurological change - one that occurs decades before dementia symptoms typically appear.
For patients and clinicians, the practical implication is timing. If risk begins shifting in midlife, then detection, monitoring, and prevention efforts aimed at women may need to start considerably earlier than current practice assumes, and be tailored to sex-specific risk factors rather than applied uniformly.
The scale of the question is large: an estimated 1.2 billion women will experience menopause by 2050. Yet Mosconi notes that relatively little research has directly investigated these sex-specific mechanisms, which is why the review frames further study as urgent rather than settled. For now, this is a case for redirecting research attention and clinical curiosity, not a finished prevention protocol.